Open Access<p>A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model</p>
Author(s) -
Isabella Orienti,
Ferro Nguyen,
Peng Guan,
Venkatadri Kolla,
Natalia Calonghi,
Giovanna Farruggia,
Michael Chorny,
Garrett M. Brodeur
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s221909
Subject(s) - fenretinide , lenalidomide , medicine , pharmacology , neuroblastoma , combination therapy , therapeutic index , toxicity , cancer research , drug , chemistry , multiple myeloma , retinoid , cell culture , biology , biochemistry , retinoic acid , genetics , gene
Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic index prevents drug-dose escalation and protracted administration schedules, as would be required for MRD treatment. Thus, more effective and less toxic therapies are urgently needed for the management of MRD. To address this aim, we evaluated a new combination of fenretinide and lenalidomide, both endowed with antitumor activity and low-toxicity profiles. New nanomicelles were prepared as carriers for this combination to maximize bioavailability and accumulation at the tumor site because of the enhanced permeability and retention (EPR) effect.